


# DACAB

**Trial design:** Patients scheduled for CABG were randomized in a 1:1:1 fashion to either aspirin 100 mg daily, ticagrelor 90 mg BID, or dual antiplatelet therapy (DAPT), resumed within 24 hours post-CABG. Patients were followed for 1 year.



## Results

- Primary outcome, SVG patency at 1 year: aspirin vs. ticagrelor vs. DAPT: 76.5% vs. 82.8% vs. 88.7%,  $p_{\text{ticag vs. aspirin}} = 0.096$ ,  $p_{\text{DAPT vs. aspirin}} = 0.0006$
- MACE: 5.4% vs. 2.4% vs. 1.8%; MI: 1.8% vs. 1.2% vs. 1.2%; stroke: 2.4% vs. 1.2% vs. 0%
- Non-CABG-related bleeding: 9% vs. 12.1% vs. 30.4%; major bleeding: 0% vs. 1.2% vs. 1.8%

## Conclusions

- DAPT with aspirin + ticagrelor results in superior SVG patency at 1 year following CABG compared to low-dose aspirin monotherapy, mostly among patients undergoing off-pump CABG
- SVG patency in aspirin arm of this trial was lower than reported from other contemporary trials